Philippe Celerier

Valence, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 22, 2025

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 22, 2025

Real-world outcomes of adjuvant therapies in stage III/IV melanoma: Insights from the French RIC-MEL cohort.

Real-world outcomes of adjuvant therapies in stage III/IV melanoma: Insights from the French RIC-MEL cohort.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 05, 2024

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Journal: Annales de dermatologie et de venereologie

Published: February 22, 2024

Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.

Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.

Journal: Acta dermato-venereologica

Published: November 14, 2023

Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database

Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database

Journal: European journal of dermatology : EJD

Published: March 01, 2023

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Journal: Annales de dermatologie et de venereologie

Published: February 07, 2023

Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial.

Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial.

Journal: Cancers

Published: June 20, 2022

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.

Journal: Cancers

Published: June 06, 2021

Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy.

Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: February 18, 2021

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.

Journal: European journal of dermatology : EJD

Published: August 21, 2020

Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.

Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.

Journal: Dermatology (Basel, Switzerland)

Published: August 01, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026